20050313
 Bristol-Myers Squibb Co.: FDA Advisory Panel Supports Hepatitis B Drug Despite Risks   The Wall Street Journal,  Mar 14, 2005  A Food and Drug Administration panel unanimously recommended the agency approve a hepatitis B treatment made by Bristol-Myers Squibb Co., saying the benefits far outweigh a possible cancer risk. The FDA usually follows the advice of its outside panels but it isn't required to do so.   
